Literature DB >> 27651329

[Merkel cell carcinoma of the eyelid. An often unrecognized tumor entity : Clinical aspects and treatment strategies].

R Hoerster1, M Schlaak2, K R Koch3, M Ortmann4, C Mauch2, L M Heindl3.   

Abstract

Merkel cell carcinoma of the eyelid is an aggressive, highly malignant tumor of the skin. Totaling approximately 0.5 % of all tumors of the eyelid, it constitutes a relatively small group of lid tumors. Nevertheless Merkel cell carcinoma is of significance to the ophthalmologist. Because of its clinical presentation it can be easily confused as a chalazion, a hordeolum or the lesser aggressive basal cell carcinoma. This often leads to delayed treatment. In this article we describe clinical aspects, which aim to help the ophthalmologist suspect Merkel cell carcinoma earlier. Additionally we outline a diagnostic and therapeutic workup taking into consideration the special anatomy of the eyelid.

Entities:  

Keywords:  Basal cell carcinoma; Chalazion; Epidemiology; Excision; Neoplasia

Mesh:

Year:  2017        PMID: 27651329     DOI: 10.1007/s00347-016-0355-0

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  37 in total

1.  Recurrence after complete resection and selective use of adjuvant therapy for stage I through III Merkel cell carcinoma.

Authors:  Ryan C Fields; Klaus J Busam; Joanne F Chou; Katherine S Panageas; Melissa P Pulitzer; Peter J Allen; Dennis H Kraus; Mary S Brady; Daniel G Coit
Journal:  Cancer       Date:  2011-11-09       Impact factor: 6.860

2.  Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system.

Authors:  Bianca D Lemos; Barry E Storer; Jayasri G Iyer; Jerri Linn Phillips; Christopher K Bichakjian; L Christine Fang; Timothy M Johnson; Nanette J Liegeois-Kwon; Clark C Otley; Kelly G Paulson; Merrick I Ross; Siegrid S Yu; Nathalie C Zeitouni; David R Byrd; Vernon K Sondak; Jeffrey E Gershenwald; Arthur J Sober; Paul Nghiem
Journal:  J Am Acad Dermatol       Date:  2010-06-19       Impact factor: 11.527

3.  [Brief guideline--cutaneous neuroendocrine carcinoma (Merkel cell carcinoma].

Authors:  Axel Hauschild; Claus Garbe
Journal:  J Dtsch Dermatol Ges       Date:  2006-06       Impact factor: 5.584

4.  Merkel cell polyomavirus-infected Merkel cell carcinoma cells require expression of viral T antigens.

Authors:  Roland Houben; Masahiro Shuda; Rita Weinkam; David Schrama; Huichen Feng; Yuan Chang; Patrick S Moore; Jürgen C Becker
Journal:  J Virol       Date:  2010-05-05       Impact factor: 5.103

5.  Correlation of American Joint Committee on Cancer T category for eyelid carcinoma with outcomes in patients with periocular Merkel cell carcinoma.

Authors:  Matthew C Sniegowski; Carla L Warneke; William H Morrison; Qasiem J Nasser; Steven J Frank; Margaret L Pfeiffer; Tarek El-Sawy; Bita Esmaeli
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2014 Nov-Dec       Impact factor: 1.746

Review 6.  Upper Eyelid Reconstruction.

Authors:  Gabriela Mabel Espinoza; Angela Michelle Prost
Journal:  Facial Plast Surg Clin North Am       Date:  2016-05       Impact factor: 1.918

Review 7.  Lower Eyelid Reconstruction.

Authors:  John B Holds
Journal:  Facial Plast Surg Clin North Am       Date:  2016-05       Impact factor: 1.918

8.  Merkel cell carcinoma in the setting of HIV infection.

Authors:  K P An; D Ratner
Journal:  J Am Acad Dermatol       Date:  2001-08       Impact factor: 11.527

9.  Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features.

Authors:  Michelle Heath; Natalia Jaimes; Bianca Lemos; Arash Mostaghimi; Linda C Wang; Pablo F Peñas; Paul Nghiem
Journal:  J Am Acad Dermatol       Date:  2008-03       Impact factor: 11.527

10.  Merkel cell carcinoma of the eyelid and periocular region.

Authors:  Helen Merritt; Matthew C Sniegowski; Bita Esmaeli
Journal:  Cancers (Basel)       Date:  2014-05-09       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.